Drug Trial Radar · NCT04083781
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
134
Actual
Start
Oct 21, 2019
Primary completion
Dec 27, 2021
Study completion Feb 21, 2027
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Sep 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B with inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use. Participants who usually only take medicine to treat bleeds (on-demand) will be placed in one of two groups. In one group, participants will get study medicine from the start of the study. In the other group, participants will continue with their normal medicine and get study medicine after 6 months. Which treatment the participant gets is decided by chance. Participants who usually take medicine to prevent bleeds (prophylaxis treatment) or who are already being treated with concizumab (study medicine) will receive the study medicine from the start of the study. Participants will get 1 injection with the study medicine every day under the skin. This participants will have to do themselves and can be done at home. The study doctor will hand out the medicine in the form of a pen-injector. The pen-injector will contain the study medicine. The study will last for about seven years. The length of time the participants will be in the study depends on when they agreed to take part or when the medicine is available for purchase in their country (31 December 2026 at the latest). The time between visits will be approximately 4 weeks for the first 6 to 12 months, depending on the group participants are in and approximately 8 weeks for the rest of the study. Participants will be asked to record information into an electronic diary during the study and may also be asked to wear an activity tracker.
Conditions
- Haemophilia A With Inhibitors
- Haemophilia B With Inhibitors
Interventions
ConcizumabDrug
Concizumab will be administered daily subcutaneously (s.c., under the skin). When patients are randomised to concizumab prophylaxis they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week 0: arm 2, 3 \& 4) or visit 9a (week 24: arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (week 6: arm 2, 3 \& 4) or 9a.3 (week 30: arm 1) and will be based on the concizumab exposure level measured at the previous visit 4a (week 4) or 9a.2 (week 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual bypassing product until visit 9a (week 24: end of main part for arm 1).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Treated Spontaneous and Traumatic Bleeding EpisodesTime frame: On demand (arm 1): From week 0 up until start of concizumab treatment (at least 24 weeks) Concizumab (arm 2): From week 0 up until the primary analysis cut-off (at least 32 weeks)
Locations
99 sites in 29 countries. Site status is shown where the registry gives one.
Center for Inherited Blood Dis
Orange, California
Children's Healthcare Atlanta
Atlanta, Georgia
Indiana Hemophilia-Thromb Ctr
Indianapolis, Indiana
Washington University School of Medicine_St. Louis
St Louis, Missouri
St. Jude Affiliate Clinic at Novant Health Hemby Children's
Charlotte, North Carolina
TriStar Medical Group Children's Specialist
Nashville, Tennessee
University of Texas San Antonio
San Antonio, Texas
Haematology and Blood Bank Department
Algiers, Algeria
CHU Constantine BEN BADIS/ Hematology department
Constantine, Algeria
The Alfred
Melbourne, Victoria, Australia
The Royal Children's Hospital
Parkville, Victoria, Australia
Fiona Stanley Hospital - Haemophilia and Haemostasis Centre
Murdoch, Western Australia, Australia
Klin. Abt. f. Hämatologie und Hämostaseologie, AKH Wien
Vienna, Austria
UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
Sofia, Bulgaria
Hamltn Hth Sci/McMstr Child Hosp
Hamilton, Ontario, Canada
KBC Zagreb, Rebro, Hemofilija centar
Zagreb, Croatia
KBC Zagreb_Hematology
Zagreb, Croatia
KBC Zagreb, Zavod za pedijatrijsku hematologiju
Zagreb, Croatia
Ustav Hematologie a krevni tranfuze
Prague, Czechia
Fakultni Nemocnice Motol A Homolka
Prague, Czechia
Skejby Blodsygdomme, blødercentret
Aarhus N, Denmark
Hospices Civils de Lyon- Hopital Louis Pradel
Bron, France
Centre Hospitalier de Clermont-Ferrand-Hopital Estaing
Clermont-Ferrand, France
Ap-Hp-Hopital de Bicetre
Le Kremlin-Bicêtre, France
Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou
Rennes, France
All India Institute of Medical Sciences_New Dehli
New Delhi, India
St. John's Medical college and Hospital
Bangalore, Karnataka, India
Sahyadri Speciality Hospital
Pune, Maharashtra, India
Sahyadri Super Speciality Hospital
Pune, Maharashtra, India
All India Institute of Medical Sciences_New Dehli
New Dehli, New Delhi, India
CMCV
Ranipet, Tamil Nadu, India
CMCV
Ranipet, Tamil Nadu, India
Istituto Oncologico Veneto - Oncoematologia IOV
Castelfranco Veneto, Italy
Oncoematologia IOV
Castelfranco Veneto, Italy
Istituto di Medicina Int. A. Bianchi Bonomi Univ. Milano
Milan, Italy
Azienda OU "S.Maria della Misericordia"
Udine, Italy
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Donna Bambino Borgo Trento - U.O.C. Oncoematologia Pediatrica
Verona, Italy
Ospedale Donna Bambino U.O.C. Oncoematologia Pediatrica
Verona, Italy
Dipartimento di Ematologia Univ. Firenze
Florence, FI, Italy
Nagoya University Hospital_Blood Transfusion
Aichi, Japan
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.